Toronto Dominion Bank Increases Stock Holdings in Organigram Holdings Inc. (NASDAQ:OGI)

Toronto Dominion Bank boosted its position in shares of Organigram Holdings Inc. (NASDAQ:OGIFree Report) by 803.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 16,727 shares of the company’s stock after purchasing an additional 14,876 shares during the period. Toronto Dominion Bank’s holdings in Organigram were worth $30,000 at the end of the most recent reporting period.

Separately, Renaissance Technologies LLC grew its position in shares of Organigram by 40.8% during the 2nd quarter. Renaissance Technologies LLC now owns 816,948 shares of the company’s stock valued at $1,258,000 after purchasing an additional 236,700 shares in the last quarter. 34.63% of the stock is owned by institutional investors and hedge funds.

Organigram Stock Performance

Organigram stock opened at $1.53 on Tuesday. The stock has a market cap of $193.02 million, a P/E ratio of -3.65 and a beta of 1.02. Organigram Holdings Inc. has a fifty-two week low of $1.21 and a fifty-two week high of $2.91. The firm’s fifty day moving average price is $1.63 and its 200-day moving average price is $1.68.

About Organigram

(Free Report)

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.

Featured Articles

Want to see what other hedge funds are holding OGI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organigram Holdings Inc. (NASDAQ:OGIFree Report).

Institutional Ownership by Quarter for Organigram (NASDAQ:OGI)

Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.